Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis.
Caldeira D, Costa J, Ferreira JJ, Lip GY, Pinto FJ. Caldeira D, et al. Clin Res Cardiol. 2015 Jul;104(7):582-90. doi: 10.1007/s00392-015-0821-8. Epub 2015 Feb 3. Clin Res Cardiol. 2015. PMID: 25643952 Review.
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are at least non-inferior to Vitamin K Antagonists (VKAs) for stroke prevention on patients with non-valvular atrial fibr …
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are at least non-inferior …
Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.
Telles-Garcia N, Dahal K, Kocherla C, Lip GYH, Reddy P, Dominic P. Telles-Garcia N, et al. Int J Cardiol. 2018 Oct 1;268:143-148. doi: 10.1016/j.ijcard.2018.04.034. Int J Cardiol. 2018. PMID: 30041779
BACKGROUND: Current guidelines recommend anticoagulation using warfarin with bridging parenteral anticoagulation or one of the non-vitamin K antagonist oral anticoagulants (NOACs) to prevent thromboembolic events in patie …
BACKGROUND: Current guidelines recommend anticoagulation using warfarin with bridging parenteral anticoagulation or one of the …